VIVXF (Avivagen) Cyclically Adjusted PB Ratio: (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Avivagen Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avivagen  (OTCPK:VIVXF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Avivagen Cyclically Adjusted PB Ratio Related Terms


Avivagen Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Avivagen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen Cyclically Adjusted PB Ratio Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VIVXF vs DMKPQ, MJNE, ACORQ: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Avivagen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avivagen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avivagen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Avivagen's Cyclically Adjusted PB Ratio falls into.



Avivagen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Avivagen's Cyclically Adjusted Book per Share for the quarter that ended in Jul. 2023 is calculated as:

For example, Avivagen's adjusted Book Value per Share data for the three months ended in Jul. 2023 was:

Adj_Book=Book Value per Share/CPI of Jul. 2023 (Change)*Current CPI (Jul. 2023)
=-0.09/124.9144*124.9144
=-0.090

Current CPI (Jul. 2023) = 124.9144.

Avivagen Quarterly Data

Book Value per Share CPI Adj_Book
201310 -0.124 97.182 -0.159
201401 -0.064 97.261 -0.082
201404 -0.072 98.920 -0.091
201407 -0.100 99.315 -0.126
201410 -0.124 99.473 -0.156
201501 -0.063 98.209 -0.080
201504 -0.080 99.710 -0.100
201507 -0.094 100.579 -0.117
201510 0.016 100.500 0.020
201601 -0.115 100.184 -0.143
201604 -0.150 101.370 -0.185
201607 -0.041 101.844 -0.050
201610 0.099 102.002 0.121
201701 0.018 102.318 0.022
201704 -0.018 103.029 -0.022
201707 -0.048 103.029 -0.058
201710 0.005 103.424 0.006
201801 0.065 104.056 0.078
201804 0.042 105.320 0.050
201807 0.027 106.110 0.032
201810 0.002 105.952 0.002
201901 -0.022 105.557 -0.026
201904 -0.024 107.453 -0.028
201907 -0.051 108.243 -0.059
201910 -0.071 107.927 -0.082
202001 -0.033 108.085 -0.038
202004 -0.051 107.216 -0.059
202007 -0.064 108.401 -0.074
202010 -0.086 108.638 -0.099
202101 -0.114 109.192 -0.130
202104 -0.017 110.851 -0.019
202107 -0.036 112.431 -0.040
202110 -0.056 113.695 -0.062
202201 -0.076 114.801 -0.083
202204 -0.043 118.357 -0.045
202207 -0.055 120.964 -0.057
202210 -0.057 121.517 -0.059
202301 -0.069 121.596 -0.071
202304 -0.079 123.571 -0.080
202307 -0.090 124.914 -0.090

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.